Hold

Average of 2 AIs

↑ Improved from previous

Last Updated: 14 Feb 2026, 08:38 pm IST | Report Date: Feb 14, 2026

Bodal Chemicals Limited Stock Analysis

Name: Bodal Chemicals Limited (BODALCHEM) Stock Analysis
Brand: NSE India
Rating: 6.1 (2 reviews)

BODALCHEM NSE India

6.5

Claude

Hold

5.6

ChatGPT

Hold

Bodal Chemicals Limited (BODALCHEM) is a India-based company listed on NSE. This AI-powered analysis provides investment insights based on quarterly earnings reports and financial performance metrics.

Share Share Share

Bodal Chemicals shows modest operational improvement with 9M FY26 consolidated revenue of Rs. 14,242 million (up 9.8% YoY) and standalone profit of Rs. 165.20 million, but Q3 performance was weak with near-zero consolidated profit of Rs. 2.42 million compared to Rs. 54.15 million in Q3 FY25. The quarter was impacted by hyperinflation accounting losses of Rs. 10.03 million from Turkish subsidiaries and new labor code provisions increasing employee costs by Rs. 17.97 million. Strategic asset monetization generated Rs. 263.50 million in gains during 9M FY26, while the company is proactively selling 39.9 acres of land to buyers who will consume byproducts (chlorine and hydrogen), indicating focus on operational efficiency and cash generation.

Based on: Bodal Chemicals Limited - Financial Results (14/2/2026) (Feb 14, 2026)

AI Investment Score & Analysis

+ Key Strengths

Revenue growth momentum with 9M FY26 consolidated revenue at Rs. 14,242 million versus Rs. 12,976 million in 9M FY25, representing 9.8% YoY growth

Strong asset monetization with Rs. 263.50 million profit from sale of non-core industrial units (Unit-II and Unit-III) during 9M FY26

Strategic byproduct management through planned sale of 39.9 acres of land to buyers who will set up units consuming chlorine and hydrogen byproducts, enabling uninterrupted production

Improved inventory management with negative change in inventories of Rs. 29.78 million in Q3 FY26 versus positive Rs. 266.58 million in Q2 FY26, indicating better stock turnover

Reduced finance costs on sequential basis at Rs. 194.41 million in Q3 FY26 versus Rs. 199.15 million in Q2 FY26, showing marginally better debt servicing efficiency

- Key Risks

Sharp profit decline in Q3 FY26 with consolidated PAT of Rs. 2.42 million versus Rs. 54.15 million in Q3 FY25, representing 95.5% YoY deterioration

Hyperinflation accounting impact from Turkish subsidiaries with Rs. 43.37 million loss for 9M FY26 and Rs. 10.03 million in Q3 FY26, creating earnings volatility

Material one-time employee cost burden of Rs. 17.97 million due to new labor codes redefining wages, permanently increasing the cost base

High other expenses at Rs. 4,422.71 million for 9M FY26 (31% of revenue), indicating cost management challenges despite revenue growth

Dependence on asset sales for profitability with Rs. 178.94 million gain in Q2 FY26 and Rs. 84.56 million in Q3 FY26, masking weak core operating performance

Foreign exchange translation losses of Rs. 22.64 million in 9M FY26 from foreign subsidiaries, adding to earnings pressure

Forward Outlook

The company is executing a strategic pivot toward operational sustainability by monetizing non-core land assets while simultaneously addressing byproduct disposal challenges through the planned sale of 39.9 acres to chlorine and hydrogen consuming industries, which should enable uninterrupted production and support top-line and bottom-line growth. The fire incident at Unit 7 (December 2024) has been fully resolved with Rs. 47.11 million insurance settlement, removing this overhang. However, near-term profitability will remain pressured by the permanent Rs. 17.97 million annual increase in gratuity costs due to new labor codes and ongoing hyperinflation losses from Turkish operations. The land sales are described as 'not substantial compared to the size of the company' and are priced at 'prevailing market rates,' suggesting limited one-time gains ahead, requiring core chemical business margins to improve for sustained earnings recovery over the next 2-4 quarters.

Detailed AI Analysis by Provider

6.5

Anthropic Claude Hold

claude-cli (Claude Code)

Forward Outlook

Strengths

Revenue growth momentum with 9M FY26 consolidated revenue at Rs. 14,242 million versus Rs. 12,976 million in 9M FY25, representing 9.8% YoY growth

Strong asset monetization with Rs. 263.50 million profit from sale of non-core industrial units (Unit-II and Unit-III) during 9M FY26

Strategic byproduct management through planned sale of 39.9 acres of land to buyers who will set up units consuming chlorine and hydrogen byproducts, enabling uninterrupted production

Improved inventory management with negative change in inventories of Rs. 29.78 million in Q3 FY26 versus positive Rs. 266.58 million in Q2 FY26, indicating better stock turnover

Reduced finance costs on sequential basis at Rs. 194.41 million in Q3 FY26 versus Rs. 199.15 million in Q2 FY26, showing marginally better debt servicing efficiency

Risks

Sharp profit decline in Q3 FY26 with consolidated PAT of Rs. 2.42 million versus Rs. 54.15 million in Q3 FY25, representing 95.5% YoY deterioration

Hyperinflation accounting impact from Turkish subsidiaries with Rs. 43.37 million loss for 9M FY26 and Rs. 10.03 million in Q3 FY26, creating earnings volatility

Material one-time employee cost burden of Rs. 17.97 million due to new labor codes redefining wages, permanently increasing the cost base

High other expenses at Rs. 4,422.71 million for 9M FY26 (31% of revenue), indicating cost management challenges despite revenue growth

Dependence on asset sales for profitability with Rs. 178.94 million gain in Q2 FY26 and Rs. 84.56 million in Q3 FY26, masking weak core operating performance

Foreign exchange translation losses of Rs. 22.64 million in 9M FY26 from foreign subsidiaries, adding to earnings pressure

5.6

OpenAI ChatGPT Hold

codex-cli (OpenAI Codex)

Overall verdict: HOLD, because Bodal shows strong nine-month reported growth but weak underlying quarterly profitability and elevated earnings volatility. Consolidated revenue grew to Rs. 4,895.69 million in Q3 FY26 (vs Rs. 4,434.66 million YoY) and to Rs. 14,242.24 million for 9M FY26 (vs Rs. 12,975.55 million), yet Q3 PAT dropped sharply to Rs. 2.42 million from Rs. 59.93 million QoQ and Rs. 54.15 million YoY, with EPS at Rs. 0.02. Reported 9M PAT improved to Rs. 157.68 million (vs Rs. 39.98 million), but this is partly supported by Other Income of Rs. 390.63 million, including Rs. 263.50 million profit on sale of non-core assets. Earnings quality is mixed as operating pressure, hyperinflation impact in Turkey (Rs. 43.37 million in 9M), and high finance costs (Rs. 609.88 million in 9M) offset top-line gains.

Forward Outlook

This quarter’s key strategic move is continued non-core land monetization, with board-approved sales of 15.1875 acres and 24.7083 acres at Unit-12 to counterparties expected to consume chlorine and hydrogen byproducts. Management explicitly links these transactions to more uninterrupted production and improvement in top line and bottom line, though sale consideration itself is stated to be not substantial versus company size. Near-term reported performance should still be watched for earnings normalization because Q3 profit was weak despite solid revenue growth, and recent 9M profit benefited materially from asset-sale gains. Over the next 2-4 quarters, the main disclosed catalysts are execution of these land-linked industrial tie-ups and operating stability after one-off accounting impacts (labour code gratuity hit and hyperinflation adjustments), with no explicit volume/margin guidance provided in the filing.

Strengths

Consolidated revenue from operations increased 10.4% YoY in Q3 (Rs. 4,895.69 million vs Rs. 4,434.66 million) and about 9.8% in 9M (Rs. 14,242.24 million vs Rs. 12,975.55 million).

9M consolidated PAT rose to Rs. 157.68 million from Rs. 39.98 million, with EPS improving to Rs. 1.25 from Rs. 0.32.

Non-core asset monetization was executed, with Rs. 263.50 million profit on sale recorded in 9M FY26 under Other Income.

Board approved further land rationalization (15.1875 acres and 24.7083 acres at Unit-12) tied to byproduct offtake (chlorine and hydrogen), indicating strategic integration intent.

Limited review reports are unmodified on both standalone and consolidated results, with auditors not flagging material misstatement.

Risks

Quarterly earnings deteriorated sharply: consolidated PAT fell to Rs. 2.42 million in Q3 FY26 from Rs. 59.93 million in Q2 and Rs. 54.15 million in Q3 FY25.

Q3 profitability was extremely thin, with PBT of Rs. 2.35 million on total income of Rs. 5,046.57 million (near break-even margin).

Finance cost remains high at Rs. 194.41 million in Q3 and Rs. 609.88 million in 9M, constraining net profitability.

Earnings are influenced by non-recurring/non-operating items, including Rs. 263.50 million asset-sale gains within 9M Other Income of Rs. 390.63 million.

International exposure adds volatility: hyperinflation accounting loss from Turkey subsidiaries was Rs. 10.03 million in Q3 and Rs. 43.37 million in 9M, while 9M OCI included negative translation impact of Rs. 22.64 million.

Score History

Score Timeline

Quarterly Report News Event

All Scores

Date	Report	Score	Sentiment	AI
Feb 14, 2026	Bodal Chemicals Limited - Financial Results (14/2/2026)	6.5	Hold	Claude
Bodal Chemicals shows modest operational improvement with 9M FY26 consolidated revenue of Rs. 14,242 million (up 9.8% YoY) and standalone profit of Rs. 165.20 million, but Q3 performance was weak with near-zero consolidated profit of Rs. 2.42 million compared to Rs. 54.15 million in Q3 FY25. The quarter was impacted by hyperinflation accounting losses of Rs. 10.03 million from Turkish subsidiaries and new labor code provisions increasing employee costs by Rs. 17.97 million. Strategic asset monetization generated Rs. 263.50 million in gains during 9M FY26, while the company is proactively selling 39.9 acres of land to buyers who will consume byproducts (chlorine and hydrogen), indicating focus on operational efficiency and cash generation. STRENGTHS: Revenue growth momentum with 9M FY26 consolidated revenue at Rs. 14,242 million versus Rs. 12,976 million in 9M FY25, representing 9.8% YoY growth / Strong asset monetization with Rs. 263.50 million profit from sale of non-core industrial units (Unit-II and Unit-III) during 9M FY26 / Strategic byproduct management through planned sale of 39.9 acres of land to buyers who will set up units consuming chlorine and hydrogen byproducts, enabling uninterrupted production / Improved inventory management with negative change in inventories of Rs. 29.78 million in Q3 FY26 versus positive Rs. 266.58 million in Q2 FY26, indicating better stock turnover / Reduced finance costs on sequential basis at Rs. 194.41 million in Q3 FY26 versus Rs. 199.15 million in Q2 FY26, showing marginally better debt servicing efficiency RISKS: Sharp profit decline in Q3 FY26 with consolidated PAT of Rs. 2.42 million versus Rs. 54.15 million in Q3 FY25, representing 95.5% YoY deterioration / Hyperinflation accounting impact from Turkish subsidiaries with Rs. 43.37 million loss for 9M FY26 and Rs. 10.03 million in Q3 FY26, creating earnings volatility / Material one-time employee cost burden of Rs. 17.97 million due to new labor codes redefining wages, permanently increasing the cost base / High other expenses at Rs. 4,422.71 million for 9M FY26 (31% of revenue), indicating cost management challenges despite revenue growth / Dependence on asset sales for profitability with Rs. 178.94 million gain in Q2 FY26 and Rs. 84.56 million in Q3 FY26, masking weak core operating performance / Foreign exchange translation losses of Rs. 22.64 million in 9M FY26 from foreign subsidiaries, adding to earnings pressure
Feb 14, 2026	Bodal Chemicals Limited - Financial Results (14/2/2026)	5.6	Hold	ChatGPT
Overall verdict: HOLD, because Bodal shows strong nine-month reported growth but weak underlying quarterly profitability and elevated earnings volatility. Consolidated revenue grew to Rs. 4,895.69 million in Q3 FY26 (vs Rs. 4,434.66 million YoY) and to Rs. 14,242.24 million for 9M FY26 (vs Rs. 12,975.55 million), yet Q3 PAT dropped sharply to Rs. 2.42 million from Rs. 59.93 million QoQ and Rs. 54.15 million YoY, with EPS at Rs. 0.02. Reported 9M PAT improved to Rs. 157.68 million (vs Rs. 39.98 million), but this is partly supported by Other Income of Rs. 390.63 million, including Rs. 263.50 million profit on sale of non-core assets. Earnings quality is mixed as operating pressure, hyperinflation impact in Turkey (Rs. 43.37 million in 9M), and high finance costs (Rs. 609.88 million in 9M) offset top-line gains. STRENGTHS: Consolidated revenue from operations increased 10.4% YoY in Q3 (Rs. 4,895.69 million vs Rs. 4,434.66 million) and about 9.8% in 9M (Rs. 14,242.24 million vs Rs. 12,975.55 million). / 9M consolidated PAT rose to Rs. 157.68 million from Rs. 39.98 million, with EPS improving to Rs. 1.25 from Rs. 0.32. / Non-core asset monetization was executed, with Rs. 263.50 million profit on sale recorded in 9M FY26 under Other Income. / Board approved further land rationalization (15.1875 acres and 24.7083 acres at Unit-12) tied to byproduct offtake (chlorine and hydrogen), indicating strategic integration intent. / Limited review reports are unmodified on both standalone and consolidated results, with auditors not flagging material misstatement. RISKS: Quarterly earnings deteriorated sharply: consolidated PAT fell to Rs. 2.42 million in Q3 FY26 from Rs. 59.93 million in Q2 and Rs. 54.15 million in Q3 FY25. / Q3 profitability was extremely thin, with PBT of Rs. 2.35 million on total income of Rs. 5,046.57 million (near break-even margin). / Finance cost remains high at Rs. 194.41 million in Q3 and Rs. 609.88 million in 9M, constraining net profitability. / Earnings are influenced by non-recurring/non-operating items, including Rs. 263.50 million asset-sale gains within 9M Other Income of Rs. 390.63 million. / International exposure adds volatility: hyperinflation accounting loss from Turkey subsidiaries was Rs. 10.03 million in Q3 and Rs. 43.37 million in 9M, while 9M OCI included negative translation impact of Rs. 22.64 million.

Related Stocks on NSE

Suprajit Engineering Limited

Sakuma Exports Limited

SAKUMA

3.5

Murudeshwar Ceramics Limited

MURUDCERA

5.5

Gujarat Kidney And Super Speciality Limited

GKSL

7.5

JSW Infrastructure Limited

IRIS RegTech Solutions Limited

IRIS

8.5

Frequently Asked Questions

What is the AI Stock Score?

The AI Stock Score is a composite rating from 0-10 generated by analyzing quarterly earnings reports using three leading AI models (Google Gemini, Anthropic Claude, and OpenAI ChatGPT). Each AI independently evaluates financial performance, growth prospects, risks, and market positioning to provide an objective investment perspective.

How should I interpret Buy/Hold/Sell ratings?

Buy (7.0-10.0): Strong fundamentals and positive outlook. Hold (4.0-6.9): Mixed signals, suitable for existing positions. Sell (0-3.9): Deteriorating fundamentals or significant risks. These are AI-generated opinions for informational purposes only, not investment advice.

How is the composite score calculated?

The composite score is the mathematical average of the latest scores from each AI provider. For example, if Gemini rates 7.5, Claude rates 4.5, and ChatGPT rates 6.0, the composite score would be (7.5+4.5+6.0)/3 = 6.0. This multi-AI approach reduces bias from any single model.

How often are scores updated?

Scores are automatically generated within hours of quarterly earnings results being published on NSE. The system monitors earnings announcements 4 times daily and processes new reports immediately. Check the "Last Updated" date at the top of this page for the most recent analysis timestamp.

Is this financial advice?

No. This is AI-generated analysis for informational and educational purposes only. MarketsHost is not a SEBI-registered Research Analyst or Investment Adviser. AI models can produce inaccurate results. Always consult a qualified financial advisor and conduct your own due diligence before making investment decisions.